L.D. of Surgical Semeiotics, Parma, Italy.
Eur Rev Med Pharmacol Sci. 2012 Dec;16(14):1925-33.
The impact of constantly developing molecular sciences on the various imaging modalities (particularly nuclear, magnetic resonance-based, optical techniques) has produced the beginning of a new complex science - the molecular imaging - that, through the exploitation of specific molecule-probes instead of nonspecific conventional contrast materials, is aimed at the characterization of the tumor-related molecular abnormalities, to adopt innovative targeted therapeutic measures, even at the genetic level.
Aim for this review is to focus on recent significant accomplishments of different molecular imaging modalities moreover outlining the challenges of current theranostic developments. EMERGING KNOWLEDGES: The spatial resolution of almost all imaging techniques is more and more increasing, so that some experimental in vivo imaging modalities can allow an extremely detailed three-dimensional resolution. From the constant developments of molecular biology it follows that, instead of relatively gross conventional diagnostic criteria on malignancies (anatomic location and size, surrounding tissue involvement, distant spread), more specific molecular imaging parameters might be adopted - such as tumor cell kinetics, genetic alterations, variety of involved growth factors - to reach, by innovative targeted drugs and biological agents, therapeutic effects at the molecular level. In animal models - particularly in cancer xenografts - the molecular imaging, through the resort to SIAFS (small animal imaging facilities), allows in vivo thorough investigations on the tumor development-related mechanisms, furthermore improving the research on pharmacokinetics and pharmacodynamics of newly developed drugs.
Current applications of molecular imaging are due to its capability of both in vivo identifying tumor early molecular abnormalities and monitoring personalized therapies. Foreseeably the research advances will tremendously expand in the near future, particularly considering that simultaneous both imaging- and therapy implications of the theranostics can improve, to the highest degree, the potential of molecular imaging.
不断发展的分子科学对各种成像模式(特别是核、磁共振、光学技术)产生了影响,从而产生了一门新的复杂科学——分子成像。该技术通过利用特异性分子探针而非非特异性传统对比剂,旨在对肿瘤相关分子异常进行特征描述,进而采取创新的靶向治疗措施,甚至在基因水平上。
本文旨在重点介绍不同分子成像模式的最新重要成果,并概述当前治疗发展的挑战。
几乎所有成像技术的空间分辨率都在不断提高,因此一些实验性体内成像模式可以实现极其详细的三维分辨率。从分子生物学的不断发展可以看出,我们可以采用更具体的分子成像参数,而不是采用相对粗略的恶性肿瘤常规诊断标准(解剖位置和大小、周围组织受累、远处扩散),例如肿瘤细胞动力学、遗传改变、涉及的生长因子种类等,通过创新的靶向药物和生物制剂,在分子水平上达到治疗效果。在动物模型中——特别是在肿瘤异种移植中——通过使用小型动物成像设备(SIAFS)进行分子成像,可以对肿瘤发展相关机制进行深入的体内研究,进一步改进对新开发药物的药代动力学和药效学的研究。
分子成像的当前应用归因于其在体内识别肿瘤早期分子异常和监测个体化治疗的能力。可以预见,研究进展将在不久的将来大大扩展,特别是考虑到治疗学的同时兼具成像和治疗的影响,可以最大限度地提高分子成像的潜力。